Unknown

Dataset Information

0

Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS, 1H, 13C and 1H-1H COSY NMR.

ABSTRACT: A new impurity was detected during high performance liquid chromatographic (HPLC) analysis of eslicarbazepine acetate active pharmaceutical ingredient. The structure of unknown impurity was postulated based on liquid chromatography mass spectrometry using electrospray ionization and ion trap analyzer (LC/ESI-IT/MS) analysis. Proposed structure of impurity was unambiguously confirmed by synthesis followed by characterization using 1H, 13C nuclear magnetic resonance spectrometry (NMR), 1H-1H correlation spectroscopy (COSY) and infrared spectroscopy (IR). Based on the spectroscopic and spectrometric data, unknown impurity was characterized as 5-carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl propionate.

SUBMITTER: Thomas S 

PROVIDER: S-EPMC5761219 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS, <sup>1</sup>H, <sup>13</sup>C and <sup>1</sup>H-<sup>1</sup>H COSY NMR.

Thomas Saji S   Paul Saroj Kumar SK   Joshi Subhash Chandra SC   Kumar Vineet V   Agarwal Ashutosh A   Vir Dharam D  

Journal of pharmaceutical analysis 20130824 5

A new impurity was detected during high performance liquid chromatographic (HPLC) analysis of eslicarbazepine acetate active pharmaceutical ingredient. The structure of unknown impurity was postulated based on liquid chromatography mass spectrometry using electrospray ionization and ion trap analyzer (LC/ESI-IT/MS) analysis. Proposed structure of impurity was unambiguously confirmed by synthesis followed by characterization using <sup>1</sup>H, <sup>13</sup>C nuclear magnetic resonance spectrome  ...[more]

Similar Datasets

Unknown Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.
| S-EPMC3689905 | biostudies-literature
Unknown Potential antihyperlipidemic polyketones from endophytic Diaporthe sp. JC-J7 in Dendrobium nobile† † Electronic supplementary information (ESI) available: 1H and 13C NMR, HSQC, HMBC, 1H–1H COSY, ROESY, IR, UV and HR-ESIMS spectra of compounds 1–11. See DOI: 10.1039/c8ra08822e
| S-EPMC9091869 | biostudies-literature
Unknown Organic Salts of Pharmaceutical Impurity p-Aminophenol.
| S-EPMC7221883 | biostudies-literature
Unknown Eslicarbazepine Acetate Modulates EEG Activity and Connectivity in Focal Epilepsy.
| S-EPMC6297144 | biostudies-literature
Unknown Evaluation of cerebral acetate transport and metabolic rates in the rat brain in vivo using 1H-[13C]-NMR.
| S-EPMC2879471 | biostudies-literature
Unknown Structure of the active pharmaceutical ingredient bismuth subsalicylate.
| S-EPMC9008038 | biostudies-literature
Unknown Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.
| S-EPMC5067651 | biostudies-literature
Unknown Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.
| S-EPMC6099471 | biostudies-literature
Unknown Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
| S-EPMC4826334 | biostudies-literature
Unknown Efficient Screening of Coformers for Active Pharmaceutical Ingredient Cocrystallization.
| S-EPMC9337750 | biostudies-literature